LIB Therapeutics Wins European Medicines Agency's Positive Opinion for Hypercholesterolaemia Drug

07:19 AM EDT, 07/24/2026 (MT Newswires) -- LIB Therapeutics' hypercholesterolaemia and mixed dyslipidaemia drug Lyrokaul was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use. The biopharmaceutical company's drug, which is available as a solution for pre-filled syringes, can reduce the levels of serum LDL-cholesterol in patients whose cholesterol is not under control, according to a Friday notice. The opinion will be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorization.